{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/634549cdd950350012c90fc5/6af342348516e9532832958b?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The rationale for CAR T-cell therapy in lupus ","description":"<p>The Lupus Hub was pleased to speak with David Isenberg, University College London Hospitals NHS Foundation Trust (UCLH), London, UK. We asked, What is the rationale for treating lupus with CAR T-cell therapy? </p><p><br></p><p>During this interview, Isenberg discusses the unmet need for effective treatment strategies in patients with severe, treatment-refractory systemic lupus erythematosus (SLE) and the scientific rationale for using CAR T-cell therapy in these patients. He highlights its potential to achieve deep and sustained B-cell depletion and induce sustained remission in patients with highly aggressive disease. He also discusses the intensive nature of the treatment and the need for further evidence to establish its optimal timing, treatment setting, and clinical application. </p><p><br></p><p>Intended for healthcare professionals. This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. </p>","author_name":"Scientific Education Support"}